Filing Details
- Accession Number:
- 0001209191-14-023493
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-03-27 17:10:57
- Reporting Period:
- 2014-03-26
- Filing Date:
- 2014-03-27
- Accepted Time:
- 2014-03-27 17:10:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1513818 | Versartis Inc. | VSAR | Pharmaceutical Preparations (2834) | 244106690 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1601363 | Advent Life Sciences Fund I Lp | 158 North Gower Street London X0 NW1 2ND | No | No | Yes | No | |
1601364 | Llp Sciences Life Advent | 158 North Gower Street London X0 NW1 2ND | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-03-26 | 1,258,086 | $0.00 | 1,258,086 | No | 4 | C | Indirect | See FN |
Common Stock | Acquisiton | 2014-03-26 | 489,253 | $0.00 | 1,747,339 | No | 4 | C | Indirect | See FN |
Common Stock | Acquisiton | 2014-03-26 | 176,813 | $0.00 | 1,924,152 | No | 4 | C | Indirect | See FN |
Common Stock | Acquisiton | 2014-03-26 | 78,228 | $0.00 | 2,002,380 | No | 4 | C | Indirect | See FN |
Common Stock | Acquisiton | 2014-03-26 | 154,178 | $0.00 | 2,156,558 | No | 4 | C | Indirect | See FN |
Common Stock | Acquisiton | 2014-03-26 | 60,000 | $21.00 | 2,216,558 | No | 4 | P | Indirect | See FN |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See FN |
No | 4 | C | Indirect | See FN |
No | 4 | C | Indirect | See FN |
No | 4 | C | Indirect | See FN |
No | 4 | C | Indirect | See FN |
No | 4 | P | Indirect | See FN |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Series B Convertible Preferred Stock | Warrants to Purchase Series B Preferred Stock | Disposition | 2014-03-26 | 506,376 | $0.00 | 506,376 | $0.45 |
Common Stock | Series B Convertible Preferred Stock | Acquisiton | 2014-03-26 | 506,376 | $0.00 | 44,031 | $0.00 |
Common Stock | Series B Convertible Preferred Stock | Disposition | 2014-03-26 | 14,468,020 | $0.00 | 1,258,086 | $0.00 |
Common Stock | Series C Convertible Preferred Stock | Disposition | 2014-03-26 | 5,626,413 | $0.00 | 489,253 | $0.00 |
Common Stock | Series D-1 Convertible Preferred Stock | Disposition | 2014-03-26 | 2,033,350 | $0.00 | 176,813 | $0.00 |
Common Stock | Series D-2 Convertible Preferred Stock | Disposition | 2014-03-26 | 899,619 | $0.00 | 78,228 | $0.00 |
Common Stock | Series E Convertible Preferred Stock | Disposition | 2014-03-26 | 1,773,049 | $0.00 | 154,178 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2014-03-26 | No | 4 | X | Indirect | |
14,468,020 | No | 4 | X | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- In connection with the completion of the Issuer's initial public offering of Common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into Common Stock on a 1-for-11.5 basis.
- Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund.
- Immediately exercisable. In connection with the closing of the Issuer's initial public offering of Common Stock the warrant to purchase Series B Convertible Preferred Stock shall automatically convert into a warrant to purchase Common Stock on a 1-for-11.5 basis if the warrant is not otherwise exercised prior to such closing.
- The securities do not have an expiration date. Each share of Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock converted automatically into shares of Common Stock in connection with the closing of the Issuer's initial public offering on March 26, 2014. Prior to its conversion into the Issuer's Common Stock, The Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock was convertible at any time at the option of the holder.